Age (yr) |
62.4 ± 6.8 |
60.0 ± 3.0 |
0.532
a
|
Body mass index (kg/m2) |
28.2 ± 1.9 |
27.6 ± 1.2 |
0.619 a
|
Number of men (n) |
7 (43.8%) |
48 (65.7%) |
0.100
b
|
Social level (n) |
|
|
|
1 |
9 (56.3%) |
24 (32.9%) |
0.211 b
|
2 |
2 (12.5%) |
16 (21.9%) |
|
3 |
5 (31.3%) |
33 (45.2%) |
|
Kidney failure (n) |
2 (12.5%) |
12 (16.4%) |
NA |
Liver failure (n) |
0 (0.0%) |
1 (1.4%) |
NA |
Number of total chronic disease (n) |
|
|
|
1 |
2 (12.5%) |
17 (23.3%) |
0.324 b
|
2 |
7 (43.8%) |
19 (26.0%) |
|
>2 |
7 (43.8%) |
37 (50.7%) |
|
Number of diseases involved in the study (n) |
|
|
|
1 |
13 (81.3%) |
60 (82.2%) |
0.929 b
|
Hypertension |
6 (37.5%) |
40 (54.8%) |
0.202
b
|
Type 2 diabetes |
5 (31.3%) |
10 (13.7%) |
|
Hypercholesterolemia |
2 (12.5%) |
10 (13.7%) |
|
2 |
3 (18.8%) |
12 (16.4%) |
0.823 b
|
Hypertension + Type 2 diabetes |
3 (18.8%) |
9 (12.3%) |
0.386
b
|
Hypertension + Hypercholesterolemia |
0 (0.0%) |
1 (1.4%) |
NA |
Type 2 diabetes + Hypercholesterolemia |
0 (0.0%) |
2 (2.8%) |
NA |
3 |
0 (0.0%) |
1 (1.4%) |
NA |
Number of different drugs prescribed |
5.6 ± 1.5 |
5.6 ± 0,8 |
0.992
a
|
Adjusted number of different drugs prescribed (n) |
|
|
|
<5 |
7 (43.8%) |
29 (39.7%) |
0.766
b
|
≥5 |
9 (56.3%) |
44 (60.3%) |
|
Side effects at the inclusion (n) |
5 (31.3%) |
15 (20.5%) |
0.352
b
|
Adherence score at the inclusion |
1.8 ± 0,6 |
2,1 ± 0,3 |
0.348
a
|
Patient with hypertension (n) |
9 (56.3%) |
51 (69.9%) |
0.292
b
|
used as primary outcome |
7 (43.8%) |
49 (67.1%) |
0.080
b
|
Patient with type II diabetes (n) |
5 (31.3%) |
22 (30.1%) |
0.930
b
|
used as primary outcome |
5 (31.3%) |
11 (15.0%) |
0.127
b
|
Patient with hypercholesterolemia (n) |
5 (31.3%) |
14 (19.2%) |
0.286
b
|
used as primary outcome |
4 (25%) |
13 (17.8%) |
0.507
b
|